Home  /  Cancers  /  Vol: 11 Núm: 1 Par: January (2019)  /  Article
ARTICLE
TITLE

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

SUMMARY

Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK+ non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK+ NSCLC patients with longitudinally assessable TP53 status treated in our institutions (n = 62). Patients with TP53 mutations at baseline (TP53mutbas, n = 23) had worse overall survival (OS) than patients with initially wild-type tumours (TP53wtbas, n = 39, 44 vs. 62 months in median, p = 0.018). Within the generally favourable TP53wtbas group, detection of TP53 mutations at progression defined a “converted” subgroup (TP53mutconv, n = 9) with inferior OS, similar to that of TP53mutbas and shorter than that of patients remaining TP53 wild-type (TP53wtprogr, 45 vs. 94 months, p = 0.043). Progression-free survival (PFS) under treatment with tyrosine kinase inhibitors (TKI) for TP53mutconv was comparable to that of TP53mutbas and also shorter than that of TP53wtprogr cases (5 and 8 vs. 13 months, p = 0.0039). Fewer TP53wtprogr than TP53mutbas or TP53mutconv cases presented with metastatic disease at diagnosis (67% vs. 91% or 100%, p < 0.05). Thus, acquisition of TP53 mutations at progression is associated with more aggressive disease, shorter TKI responses and inferior OS in ALK+ NSCLC, comparable to primary TP53 mutated cases.

 Articles related

M. EL-KALAMAWY,S. EL-HADDAD,S. H. ABDEL-AZIZ,HANAN A. FAHMY    

Two novel mutants of the hepatitis B virus surface antigen (HBsAg) were characterized. The mutants that were isolated from asymptomatic patients were found to be persistently positive for both HBsAg and anti-hepatitis B surface antibody (anti-HBs) and a ... see more


Paul Hofman    

Patients with advanced-stage non-small cell lung carcinoma (NSCLC) harboring an ALK rearrangement, detected from a tissue sample, can benefit from targeted ALK inhibitor treatment. Several increasingly effective ALK inhibitors are now available for treat... see more

Revista: Cancers

     

Chronic Myelogenous Leukaemia (CML) is a myeloproliferative neoplasm (MPN) with clonal proliferation of all myeloid cell lines which originates in an abnormal pluripotent bone marrow stem cell. CML is characterized by the t(9;22)(q34;q11) translocation i... see more


     

Haemoglobin (Hb) gene mutations are common, estimated 7% of the world’s population affected. These mutations are broadly subdivided into those that impair globin protein subunit production (thalassemia) and those that produce structurally abnormal g... see more


Ayu Dewi Ni Nyoman,Ni Made Pramita Widya Suksmarini,Anak Agung Ngurah Satya Pranata,Andreliano Yosua Rompis,I Wayan Juli Sumadi    

Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog gene) and BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene play a significant role in primary resistance to colorectal cancer therapy. Around 85-90% of KRAS mutations in colorect... see more